{"gene":"PRKCB","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2002,"finding":"PKCβ is specifically required for BCR-mediated NF-κB activation; PKCβ-deficient B cells fail to recruit the IKK complex into lipid rafts, activate IKK, or degrade IκB, placing PKCβ upstream of IKK in the BCR survival signaling pathway.","method":"PKCβ knockout mice, lipid raft fractionation, IKK activity assays, IκB degradation assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal biochemical readouts (raft fractionation, IKK activation, IκB degradation), replicated in pharmacological inhibition studies","pmids":["12118249"],"is_preprint":false},{"year":2001,"finding":"PKCβ acts as a feedback inhibitor of Btk activation by phosphorylating a conserved serine in the Tec homology domain linker of Btk; mutation of this site enhances Btk tyrosine phosphorylation, membrane association, and augmented BCR/FcεRI-mediated signaling.","method":"PKCβ knockout mice, site-directed mutagenesis of Btk phosphorylation site, Ca2+ signaling assays, membrane fractionation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis of identified phosphorylation site combined with KO mouse and functional signaling readouts","pmids":["11598012"],"is_preprint":false},{"year":2010,"finding":"PKCβI phosphorylates histone H3 at threonine 6 (H3T6ph) during androgen receptor (AR)-dependent gene activation, preventing LSD1 from demethylating H3K4 (but not H3K9), thereby writing a new chromatin mark that maintains active methylation states. PKCβI is recruited to AR target gene promoters after androgen stimulation, requiring prior activation by the gatekeeper kinase PRK1.","method":"In vitro histone peptide LSD1 demethylation assays, ChIP, RNAi knockdown, in vivo tumor xenograft, in vitro kinase assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, mutagenesis-equivalent peptide assay, ChIP, RNAi with rescue, and in vivo xenograft in one study","pmids":["20228790"],"is_preprint":false},{"year":2013,"finding":"In differentiated osteoclasts, RANKL activates PKCβ, which phosphorylates the transcription factor TFEB on three serine residues in its C-terminal 15 amino acids, stabilizing and activating TFEB to promote lysosomal biogenesis necessary for bone resorption.","method":"Cell-based phosphorylation assays, osteoclast-specific gene deletion in mice, cell size/lysosomal gene expression assays, Western blot","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — biochemical phosphorylation mapping combined with conditional KO in mice and multiple cellular readouts","pmids":["23599343"],"is_preprint":false},{"year":2013,"finding":"PKCβ phosphorylates Ser582 in the helical domain of the PI3Kγ catalytic subunit p110γ in response to FcεRI clustering and/or store-operated Ca2+ influx in mast cells, correlating with release of the p84 adapter subunit from the p84-p110γ complex and increased p110γ activity, thereby disconnecting PI3Kγ from its canonical GPCR inputs.","method":"In vitro kinase assay, phospho-mimicking mutagenesis, Co-IP, hydrogen-deuterium exchange mass spectrometry, PKCβ knockout cells","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — phosphorylation site identified with kinase assay, phospho-mimetic mutagenesis, HDX-MS structural analysis, and KO validation","pmids":["23824069"],"is_preprint":false},{"year":2006,"finding":"RACK1 anchors activated PKCβ specifically on melanosome membranes, allowing PKCβ (but not PKCα) to phosphorylate tyrosinase on specific serine residues on its cytoplasmic domain, activating melanogenesis. Disruption of RACK1-PKCβ interaction with DECA or siRNA knockdown of RACK1 decreases tyrosinase activity.","method":"Melanosome purification, co-immunoprecipitation, siRNA knockdown of RACK1, tyrosinase activity assays, DECA pharmacological disruption","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP from purified organelle fraction, siRNA knockdown, pharmacological disruption, and functional enzyme assay","pmids":["15252133"],"is_preprint":false},{"year":2010,"finding":"In B cells, TRPC3 serves as both a Ca2+-permeable channel and a direct protein scaffold for PKCβ at the plasma membrane; TRPC3 deficiency impairs DAG-activated Ca2+ currents and the sustained BCR-stimulated translocation of PKCβ to the plasma membrane, preventing downstream ERK activation.","method":"TRPC3-deficient DT40 B cells, electrophysiology, PKCβ translocation imaging, Co-IP (direct PKCβ-TRPC3 association), ERK activation assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with direct protein-protein interaction (Co-IP) and functional signaling readouts","pmids":["20179100"],"is_preprint":false},{"year":2011,"finding":"PKCα and PKCβ phosphorylate RIG-I at S8 and T170, suppressing TRIM25 binding and K63-linked ubiquitination of RIG-I, thereby negatively regulating RIG-I antiviral IFN signaling under normal conditions. PKCα/β interact with RIG-I under normal (unstimulated) conditions.","method":"Co-immunoprecipitation, site-directed mutagenesis of RIG-I S8/T170, gene silencing, pharmacological inhibition, IFN induction assays, VSV infection resistance assays","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutagenesis, Co-IP, siRNA knockdown, and inhibitor treatment with multiple orthogonal functional assays","pmids":["22114345"],"is_preprint":false},{"year":2022,"finding":"tPA activates PKCβ, which phosphorylates occludin at serine 490 (S490) in the ischemic penumbra, increasing cerebrovascular permeability and the risk of hemorrhagic transformation. Blocking S490 phosphorylation with a non-phosphorylatable occludin (S490A) or PKCβ inhibition reduces permeability and intracerebral hemorrhage.","method":"Mouse MCAO model (tPA-/- mice), intraventricular tPA injection, S490A occludin knock-in, PKCβ pharmacological inhibition, permeability assays, Western blot","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (KO mice, non-phosphorylatable mutant) and pharmacological approaches with multiple in vivo functional readouts","pmids":["35576527"],"is_preprint":false},{"year":2010,"finding":"H2O2 activates a PKCβ/p66Shc/NF-κB signaling cascade in osteoblastic cells; p66Shc is an essential mediator of H2O2-induced apoptosis and NF-κB activation downstream of PKCβ. Estrogens and androgens attenuate these effects by suppressing PKCβ phosphorylation via a non-nuclear (membrane-initiated) mechanism.","method":"H2O2 treatment of mesenchymal/osteoblastic cell models, siRNA knockdown of p66Shc, polymeric estradiol (non-nuclear ER action), Western blot, apoptosis assays","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis and pharmacological approaches in a single lab with two orthogonal methods (knockdown + non-nuclear estradiol)","pmids":["20685851"],"is_preprint":false},{"year":2012,"finding":"PRKCB (PKCβ) phosphorylates histone H3T6 to globally maintain H3K4 trimethylation at gene promoters in Ewing sarcoma cells; transcriptional activation of PRKCB is directly regulated by the EWSR1-FLI1 chimeric oncogene. PRKCB loss induces apoptosis in vitro and prevents tumor growth in vivo.","method":"Gene expression profiling, ChIP for H3T6ph/H3K4me3, siRNA/shRNA knockdown of PRKCB, in vivo xenograft models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and gene expression profiling with KD/KO phenotype, single lab","pmids":["22930730"],"is_preprint":false},{"year":2010,"finding":"PKCβ activates HuR (ELAV protein) via phosphorylation in the diabetic retina, increasing HuR binding to VEGF mRNA and stabilizing it, leading to enhanced VEGF protein expression. PKCβ inhibition blocks this PKCβ/HuR/VEGF pathway.","method":"Streptozotocin diabetic rat model, immunoprecipitation/RT-PCR (RNP complexes), PKCβ inhibitor treatment, Western blot for HuR phosphorylation","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNP immunoprecipitation with RT-PCR showing direct HuR-VEGF mRNA interaction, inhibitor treatment, single lab","pmids":["20599775"],"is_preprint":false},{"year":2012,"finding":"PKCβ activation induced by diabetes decreases GLP-1 receptor (GLP-1R) expression in glomerular endothelial cells by increasing its ubiquitination-dependent degradation and enhancing phospho-c-Raf(Ser338)/ERK1/2 activation by angiotensin II.","method":"EC-PKCβ2 transgenic mice, siRNA knockdown of GLP-1R, Western blot, ubiquitination assays","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse model plus siRNA with biochemical mechanistic endpoint (ubiquitination), single lab","pmids":["22826029"],"is_preprint":false},{"year":2013,"finding":"PKCβ activates the RhoA/Rho-kinase/MLC2 pathway in brain microvascular endothelial cells exposed to high glucose, leading to decreased occludin expression, cytoskeletal changes, and blood-brain barrier dysfunction.","method":"siRNA knockdown of PKCβ, PKCβ inhibitor (LY333531), transendothelial electrical resistance, FITC-dextran permeability, Rho activity assays, Western blot","journal":"Journal of cerebral blood flow and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological inhibition with pathway positioning (PKCβ → RhoA/ROCK/MLC2), single lab","pmids":["23963366"],"is_preprint":false},{"year":2004,"finding":"PKCβ activation in osteoblastic cells mediates PTH-, TNF-α-, and IL-1β-stimulated IL-6 promoter activation and PTH-stimulated bone resorption; PTH/TNF-α/IL-1β induces translocation of PKCβI (but not PKCα) to the plasma membrane, and this translocation is blocked by a selective PKCβ antagonist (LY379196).","method":"PKCβ translocation assays, IL-6 promoter-luciferase reporter, selective PKCβ inhibitor (LY379196), fetal rat bone organ culture resorption assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibition with reporter assay and ex vivo bone resorption, single lab, multiple readouts","pmids":["11478844"],"is_preprint":false},{"year":2017,"finding":"PKCβ-dependent activation of FAK is required for B cell mechanosensing; PMA-induced PKCβ activation can bypass Btk and PLCγ2 to activate FAK, which potentiates B cell spreading and adhesion. FAK inactivation or deficiency impairs B cell discrimination of substrate stiffness.","method":"PKCβ pharmacological activation (PMA), FAK inhibitor/KO, B cell spreading assays on substrates of varying stiffness, signaling Western blots","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis (PKCβ bypasses Btk/PLCγ2 to activate FAK), FAK KO confirmation, multiple substrate stiffness conditions","pmids":["28755662"],"is_preprint":false},{"year":2006,"finding":"RBCK1 binds PKCβI and is a key regulator of PKCβI function in cardiac myocytes; RBCK1 overexpression induces cardiac cell hypertrophy in a PKCβ-dependent manner, and RNAi of RBCK1 inhibits phenylephrine-induced hypertrophy. RBCK1 association with PKCβI increases transiently upon phenylephrine stimulation.","method":"Co-immunoprecipitation, adenoviral RBCK1 overexpression, siRNA knockdown of RBCK1, PKCβ-selective antagonist treatment, cardiomyocyte cell size measurements","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, siRNA and OE epistasis, PKCβ inhibitor rescue, single lab","pmids":["17121852"],"is_preprint":false},{"year":1999,"finding":"PKCβ mediates PMA-dependent stimulation of Na+,K+-ATPase in proximal tubule cells, while PKCζ mediates dopamine-dependent inhibition; these two isoforms exert opposing effects on Na+,K+-ATPase activity, as demonstrated with isoform-specific inhibitor peptides and LY333531.","method":"Isoform-specific PKC inhibitor peptides, LY333531 (PKCβ inhibitor), Na+,K+-ATPase activity assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific inhibitory peptides and pharmacological inhibition with functional enzyme assay, single lab","pmids":["10452527"],"is_preprint":false},{"year":2013,"finding":"PRKCB (PKCβ) activation negatively modulates mitochondrial membrane potential and inhibits autophagy; pharmacological PRKCB inhibition and PRKCB knockout MEFs show increased autophagy and increased mitochondrial membrane potential, placing PRKCB upstream of mitochondrial energy status in the regulation of autophagy.","method":"PKCβ pharmacological inhibitor, prkcb knockout MEFs, autophagy flux assays, mitochondrial membrane potential measurements","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition with functional autophagy and mitochondrial readouts, single lab","pmids":["23778835"],"is_preprint":false},{"year":2016,"finding":"PKCβ mediates MIF-induced IL-8 production in bone marrow mesenchymal stromal cells via MIF receptor CD74; this IL-8 supports AML blast survival, placing PKCβ in a MIF→CD74→PKCβ→IL-8 stromal signaling axis.","method":"Recombinant MIF treatment, MIF inhibitor (ISO-1), PKCβ inhibitor, co-culture assays, cytokine ELISA","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological epistasis positioning PKCβ downstream of CD74/MIF, functional IL-8/survival readouts, single lab","pmids":["27872094"],"is_preprint":false},{"year":2008,"finding":"PKCβ contributes to lung ischemia/reperfusion injury by coordinated activation of ERK1/2 and JNK MAPKs and induction of Egr-1 (early growth response-1) and its downstream target genes, particularly in mononuclear phagocytes; PKCβ null mice and ruboxistaurin treatment reduce these responses and improve survival.","method":"PKCβ knockout mice, ruboxistaurin pharmacological inhibition, murine single-lung I/R model, MAPK phosphorylation Western blots, Egr-1 expression assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition, multiple molecular readouts, single lab","pmids":["15173888"],"is_preprint":false},{"year":2008,"finding":"PKCβII mediates myocardial ischemia/reperfusion injury at least in part via JNK phosphorylation and caspase-3 activation; PKCβ null mice and ruboxistaurin treatment show decreased infarct size, improved LV function, and reduced JNK phosphorylation/caspase-3 activation.","method":"PKCβ knockout mice, ruboxistaurin treatment, coronary artery occlusion/reperfusion model, JNK/caspase-3 Western blots, infarct size measurement","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition with mechanistic pathway (PKCβ→JNK→caspase-3), single lab","pmids":["18245560"],"is_preprint":false},{"year":2005,"finding":"PKCβ is required for neointimal expansion after acute arterial injury; PKCβII regulates vascular smooth muscle cell migration and proliferation, at least in part via ERK1/2 MAPK and Egr-1 transcription factor activation.","method":"PKCβ knockout mice, ruboxistaurin treatment, femoral artery denudation injury model, ERK1/2 and Egr-1 expression assays, in vitro SMC assays","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition with in vivo and in vitro mechanistic readouts, single lab","pmids":["15662033"],"is_preprint":false},{"year":2008,"finding":"PKCβII activation in aortic endothelial cells is a critical upstream regulator of Egr-1 and MMP-2 in response to oxLDL via a PKCβ-JNK MAPK pathway; loss of PKCβ in apoE-/- mice reduces atherosclerotic lesion area with concomitant reductions in Egr-1 and MMP-2.","method":"PKCβ/apoE double-KO mice, ruboxistaurin pharmacological inhibition, primary endothelial cell PKCβ/JNK inhibitor experiments, MMP-2 activity assays, lesion quantification","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — double-KO mice with multiple mechanistic endpoints, single lab","pmids":["19036858"],"is_preprint":false},{"year":2015,"finding":"PKCβ activation in diabetes reduces IL-18BP expression in endothelial cells, leading to unrestrained IL-18 signaling, VCAM-1 upregulation, and increased monocyte adhesion; siRNA, ruboxistaurin, and IL-18 neutralizing antibody each prevent elevated VCAM-1 and monocyte adherence.","method":"ApoE-/- diabetic mouse model with ruboxistaurin, siRNA knockdown of PKCβ/GLP-1R, EC/macrophage high-glucose treatment, monocyte adhesion assays, VCAM-1 Western blot","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological inhibition with in vivo and in vitro functional readouts, single lab","pmids":["25808972"],"is_preprint":false},{"year":2016,"finding":"Usp9X is required for induction of PKCβ kinase activity after BCR-dependent activation in B lymphocytes; in Usp9X knockout B cells, PKCβ activity is reduced, leading to decreased CARMA1 phosphorylation, reduced CARMA1/Bcl-10/MALT-1 complex formation, and impaired NF-κB-dependent cell survival.","method":"Usp9X conditional knockout mice, BCR stimulation, CARMA1 phosphorylation/complex assays, NF-κB reporter, B cell survival assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with multiple downstream biochemical readouts placing Usp9X→PKCβ→CARMA1→NF-κB, single lab","pmids":["26936881"],"is_preprint":false},{"year":2015,"finding":"PKCβ specifically interacts with and activates PKD1 in GPCR-stimulated neutrophils; PKCβ-PKD1 interaction and signaling are required for GPCR-mediated phosphorylation of the cofilin phosphatase SSH2, actin cytoskeletal reorganization, and neutrophil chemotaxis.","method":"Co-IP of PKCβ-PKD1, siRNA knockdown, pharmacological inhibition, neutrophil chemotaxis assays, cofilin phosphorylation assays","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct PKCβ-PKD1 Co-IP plus functional chemotaxis assay with siRNA epistasis, single lab","pmids":["25568344"],"is_preprint":false},{"year":2011,"finding":"PKCβ phosphorylates glycine transporter 1 (GlyT1) on serine/threonine residues (not tyrosine); while classical PKCα/β regulate GlyT1 uptake, PKCβ-specific inhibitors selectively block GlyT1 phosphorylation without affecting glycine uptake, suggesting distinct roles for PKCα versus PKCβ in GlyT1 regulation.","method":"[32P]-orthophosphate metabolic labeling, isoform-selective PKC inhibitors (Gö6976, LY333531), glycine uptake assays in stably-transfected cells","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct phosphorylation labeling with isoform-selective inhibitors and functional transport assays, single lab","pmids":["21864610"],"is_preprint":false},{"year":2001,"finding":"Conditional expression of PKCβ in cardiac myocytes increases peak Ca2+ transient amplitude, extent and rate of shortening, and rate of relengthening, without altering phospholamban phosphorylation or SR Ca2+ uptake rates; at 10 months, maximum tension is depressed with increased myofilament protein phosphorylation.","method":"Transgenic mouse model with conditional PKCβ expression, Ca2+ transient measurements, sarcomere shortening assays, SR vesicle Ca2+-uptake assays, skinned fiber mechanics, Western blot","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional transgenic with multiple functional cardiac readouts, single lab","pmids":["11287324"],"is_preprint":false},{"year":2016,"finding":"PKCβ-mediated phosphorylation of p66Shc occurs at Ser139 and Ser213 (not Ser36 as previously proposed), regulating p66Shc pro-oxidant and pro-apoptotic function; phosphomimetic mutation of Thr206 and Ser213 produces gain-of-function with increased ROS and cell death.","method":"In vitro kinase assay, site-directed mutagenesis of p66Shc phosphorylation sites, ROS measurements, cell death assays, PKCβ knockout cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro phosphorylation assay with mutagenesis and functional ROS/apoptosis readouts, single lab; CONTRADICTS prior Ser36 claim","pmids":["27624939"],"is_preprint":false},{"year":2002,"finding":"PKCβ activation mediates HNE (4-hydroxynonenal)-induced MCP-1 release from murine macrophages, a distinct mechanism from LPS-induced MCP-1 secretion (which involves PKCδ).","method":"PKC isoform activity assays, pharmacological PKC inhibitors, MCP-1 ELISA in macrophages","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibition with a single functional readout (MCP-1), single lab, no direct PKCβ-target interaction shown","pmids":["12056801"],"is_preprint":false},{"year":2008,"finding":"Listeria monocytogenes PI-PLC promotes escape from the macrophage phagosome by generating diacylglycerol that activates host PKCβ; in PKCβ knockout macrophages, Listeria uses a PC-PLC-dependent (PKCβ-independent) pathway instead, demonstrating that PI-PLC-facilitated escape specifically requires host PKCβ.","method":"PKCβ knockout bone marrow-derived macrophages, bacterial escape assays, PI-PLC and PC-PLC mutant Listeria strains","journal":"Microbial pathogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with bacterial mutants defining a specific pathway (PI-PLC→DAG→PKCβ for phagosome escape), single lab","pmids":["18996181"],"is_preprint":false},{"year":2002,"finding":"Stress-induced AChE-R splice variant interacts intraneuronally with the scaffold protein RACK1, and through RACK1, with PKCβII in stress-responsive brain regions; elevated AChE-R is associated with increased RACK1/PKCβII co-localization and prolonged fear-induced behavioral inhibition.","method":"Co-immunoprecipitation of RACK1-PKCβII, antisense prevention of AChE-R, transgenic mice overexpressing AChE-R, immunohistochemistry, open-field behavioral testing","journal":"Proceedings of the National Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and transgenic model with functional behavioral readout, single lab","pmids":["12509514"],"is_preprint":false},{"year":1999,"finding":"Glycated albumin (Amadori-modified) activates PKCβ (specifically PKCβ1 membrane translocation) in glomerular mesangial cells under physiological glucose concentrations, and this PKCβ activation is causally linked to increased collagen type IV production, as demonstrated by beta-specific PKC inhibitors.","method":"PKCβ-specific inhibitor (LY-379196), PKCβ1 membrane fractionation, PKC activity assay, collagen IV production assay","journal":"The American journal of physiology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibition with isoform-specific compound and membrane translocation assay, functional collagen readout, single lab","pmids":["10330050"],"is_preprint":false},{"year":2020,"finding":"Chronic morphine activates MOR-PLC-PKCβ signaling, which phosphorylates TRPM8 at consensus PKC sites S1040 and S1041; this reduces TRPM8 desensitization and promotes TRPM8 hyperexcitability and cold hyperalgesia. Site-directed mutation of S1040/S1041 prevents MOR-induced TRPM8 desensitization reduction.","method":"Site-directed mutagenesis of TRPM8 S1040/S1041, PKCβ pharmacological inhibition, DRG neuronal electrophysiology, cold hyperalgesia behavioral assays in mice","journal":"Molecular brain","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis of phosphorylation sites with functional channel desensitization assays and in vivo behavioral confirmation, single lab","pmids":["32290846"],"is_preprint":false},{"year":2014,"finding":"PKCβ positively regulates RANKL-induced osteoclastogenesis by phosphorylating and inactivating GSK-3β, leading to NFATc1 induction. PKCβ expression increases in response to RANKL, and pharmacological or siRNA inhibition of PKCβ suppresses GSK-3β phosphorylation, NFATc1, and osteoclast differentiation.","method":"PKCβ pharmacological inhibition, siRNA knockdown, GSK-3β phosphorylation Western blot, NFATc1 induction assays, RANKL-injected mouse calvaria model","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological epistasis identifying PKCβ→GSK-3β→NFATc1 axis, in vivo confirmation, single lab","pmids":["25256217"],"is_preprint":false},{"year":2004,"finding":"PKCβ mediates serine phosphorylation of IRS-1 in adipocytes; overexpression of PKCβ induces IRS-1 mobility shift and serine phosphorylation and decreases insulin-stimulated glucose uptake, while dominant-negative PKCβ blocks these effects and enhances glucose uptake.","method":"In vitro PKC phosphorylation of immunoprecipitated IRS-1, PKCβ overexpression and dominant-negative PKCβ in adipocytes, 2-DOG uptake assays, Western blot","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay with functional overexpression/dominant-negative epistasis, single lab","pmids":["15473137"],"is_preprint":false},{"year":2020,"finding":"PKCβ mediates pulmonary vasoconstriction through interaction with the scaffolding protein PICK1 at mitochondria; PKCβ acutely translocates to mitochondria upon stimulation and activates mitoKATP channels, leading to mitochondrial ROS generation that drives vasoconstriction and pulmonary hypertension after intermittent hypoxia.","method":"Subcellular fractionation, proximity ligation assay (PKCβ-PICK1), mitoKATP inhibitors, antioxidant/PKCβ inhibitor in vivo, PKCβ inhibitor LY-333531, pulmonary artery contractility assays","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity ligation for PKCβ-PICK1 interaction, subcellular fractionation showing mitochondrial translocation, functional vasoconstriction assay with pharmacological inhibition, single lab","pmids":["32048876"],"is_preprint":false},{"year":2021,"finding":"lncRNA VEAL2 competes with diacylglycerol for binding to PRKCB2 and regulates its kinase activity; VEAL2 overexpression and knockdown modulate endothelial tubulogenesis and permeability, and VEAL2 can rescue PRKCB2-mediated turnover of junctional proteins.","method":"VEAL2 pulldown using PRKCB2 as bait, zebrafish veal2 knockout (cranial hemorrhage), HUVEC overexpression/knockdown, kinase activity assays, hyperglycemic HUVEC model","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein-RNA interaction with PRKCB2 bait, kinase activity assay, zebrafish KO phenotype, single lab with multiple orthogonal methods","pmids":["34180064"],"is_preprint":false}],"current_model":"PRKCB (PKCβ) is a diacylglycerol/Ca2+-activated serine/threonine kinase that phosphorylates diverse substrates to regulate B cell receptor signaling (inhibiting Btk membrane localization and activating NF-κB via IKK lipid raft recruitment), chromatin state (writing H3T6ph to prevent LSD1 demethylation of H3K4 during AR-dependent transcription), lysosomal biogenesis in osteoclasts (via TFEB phosphorylation downstream of RANKL), vascular permeability (via occludin S490 phosphorylation), mitochondrial ROS-linked apoptosis (via p66Shc phosphorylation), autophagy suppression (via mitochondrial membrane potential regulation), and antiviral innate immunity (by phosphorylating RIG-I at S8/T170 to suppress TRIM25-mediated ubiquitination and IFN induction), while being regulated by scaffold proteins RACK1 and TRPC3 for spatial control of its activity."},"narrative":{"mechanistic_narrative":"PRKCB (PKCβ) is a diacylglycerol/Ca2+-activated serine/threonine kinase that transduces receptor-proximal signals into transcriptional, cytoskeletal, metabolic, and chromatin outputs across immune, vascular, skeletal, and neuronal contexts [PMID:12118249, PMID:20228790, PMID:23599343]. In B-cell receptor signaling it occupies a central node: it is required to recruit and activate the IKK complex in lipid rafts to drive NF-κB-dependent survival [PMID:12118249], acts upstream of CARMA1 phosphorylation and CARMA1/Bcl-10/MALT-1 assembly [PMID:26936881], and simultaneously imposes negative feedback by phosphorylating a conserved serine in the Btk Tec-homology linker to limit Btk membrane recruitment [PMID:11598012]. Beyond signaling, PKCβI functions as a chromatin-modifying kinase, writing the histone mark H3T6ph to block LSD1-mediated demethylation of H3K4 and thereby sustain androgen-receptor- and EWSR1-FLI1-driven transcription [PMID:20228790, PMID:22930730]. It controls transcription-factor activity and organelle programs downstream of RANKL by phosphorylating TFEB to drive lysosomal biogenesis for bone resorption [PMID:23599343] and by inactivating GSK-3β to induce NFATc1 during osteoclastogenesis [PMID:25256217]. PKCβ further phosphorylates a broad substrate set to regulate vascular barrier integrity via occludin Ser490 [PMID:35576527], mitochondrial ROS and apoptosis via p66Shc [PMID:27624939], antiviral innate immunity by phosphorylating RIG-I at S8/T170 to suppress TRIM25-mediated ubiquitination and IFN induction [PMID:22114345], and ion-channel/transporter behavior including TRPM8 and PI3Kγ p110γ [PMID:32290846, PMID:23824069]. Its spatial activity is constrained by scaffolds and regulators including RACK1, TRPC3, PICK1, and the lncRNA VEAL2, which target or tune the kinase at melanosomes, plasma membrane, and mitochondria [PMID:15252133, PMID:20179100, PMID:32048876, PMID:34180064].","teleology":[{"year":2001,"claim":"Established that PKCβ is not only an activator of BCR signaling but also a built-in brake, defining how the pathway is self-limiting.","evidence":"PKCβ knockout mice plus site-directed mutagenesis of the Btk Tec-homology linker serine with Ca2+ and membrane-fractionation readouts","pmids":["11598012"],"confidence":"High","gaps":["Did not resolve how PKCβ access to Btk is spatially or temporally gated","Did not connect this feedback to the parallel NF-κB-activating arm"]},{"year":2002,"claim":"Placed PKCβ genetically upstream of IKK in BCR survival signaling, answering where the kinase acts in NF-κB activation.","evidence":"PKCβ knockout B cells with lipid raft fractionation, IKK activity, and IκB degradation assays","pmids":["12118249"],"confidence":"High","gaps":["Direct IKK or scaffold substrate of PKCβ not identified","Mechanism of IKK raft recruitment left unresolved"]},{"year":2006,"claim":"Showed scaffold-directed targeting confers substrate and isoform specificity, explaining how PKCβ but not PKCα acts on a given organelle target.","evidence":"Melanosome purification with reciprocal Co-IP, RACK1 siRNA, DECA disruption, and tyrosinase activity assays","pmids":["15252133"],"confidence":"High","gaps":["Tyrosinase phosphosites not precisely mapped","Generality of RACK1-PKCβ targeting beyond melanosomes untested here"]},{"year":2010,"claim":"Redefined PKCβI as a chromatin-modifying enzyme, showing a kinase can write a histone mark that protects an adjacent methyl mark from erasure.","evidence":"In vitro LSD1 peptide demethylation assays, ChIP, RNAi with rescue, in vitro kinase assay, and tumor xenograft","pmids":["20228790"],"confidence":"High","gaps":["How PRK1-primed PKCβI is recruited to specific AR promoters not fully resolved","Genome-wide scope of H3T6ph not defined"]},{"year":2010,"claim":"Demonstrated TRPC3 acts as both Ca2+ channel and direct scaffold, coupling DAG/Ca2+ signals to sustained PKCβ membrane residence.","evidence":"TRPC3-deficient DT40 B cells with electrophysiology, translocation imaging, Co-IP, and ERK readouts","pmids":["20179100"],"confidence":"High","gaps":["Structural basis of the TRPC3-PKCβ interaction unknown","Whether scaffold dictates substrate choice not addressed"]},{"year":2011,"claim":"Identified PKCα/β as constitutive negative regulators of antiviral IFN signaling through direct RIG-I phosphorylation.","evidence":"Co-IP, RIG-I S8/T170 mutagenesis, gene silencing, inhibitor treatment, IFN induction and VSV resistance assays","pmids":["22114345"],"confidence":"High","gaps":["How infection relieves PKCβ-mediated suppression not defined","Relative contributions of PKCα versus PKCβ not separated"]},{"year":2013,"claim":"Connected RANKL signaling to organelle biogenesis by mapping PKCβ phosphorylation of TFEB to lysosome-dependent bone resorption.","evidence":"Cell-based phosphorylation mapping of TFEB C-terminal serines, osteoclast-specific KO mice, lysosomal gene readouts","pmids":["23599343"],"confidence":"High","gaps":["How phosphorylation stabilizes TFEB mechanistically not fully resolved","Crosstalk with other TFEB kinases not addressed"]},{"year":2013,"claim":"Extended PKCβ substrate scope to lipid kinase regulation, showing it can rewire PI3Kγ away from its canonical GPCR inputs.","evidence":"In vitro kinase assay, phospho-mimetic mutagenesis, Co-IP, HDX-MS, and PKCβ knockout cells","pmids":["23824069"],"confidence":"High","gaps":["In vivo consequences of p110γ Ser582 phosphorylation not established","Effect on PI3Kγ output magnitude beyond p84 release unquantified"]},{"year":2016,"claim":"Revised the p66Shc phosphosite assignment, refining how PKCβ controls mitochondrial ROS and apoptosis.","evidence":"In vitro kinase assay, mutagenesis of p66Shc Ser139/Ser213, ROS and cell-death readouts, PKCβ knockout cells","pmids":["27624939"],"confidence":"Medium","gaps":["Contradicts prior Ser36 model and not independently confirmed","Upstream activation of PKCβ in this cascade not detailed"]},{"year":2022,"claim":"Defined a specific occludin phosphosite (S490) through which PKCβ governs vascular permeability and hemorrhagic risk.","evidence":"MCAO model in tPA-/- mice, S490A occludin knock-in, PKCβ inhibition, permeability and hemorrhage readouts","pmids":["35576527"],"confidence":"High","gaps":["How tPA activates PKCβ upstream not mechanistically mapped","Whether other junctional substrates contribute not addressed"]},{"year":2021,"claim":"Showed PKCβ2 activity is tuned by a noncoding RNA competing with its lipid activator, adding an RNA-level layer of kinase regulation.","evidence":"VEAL2 pulldown with PRKCB2 bait, kinase activity assays, zebrafish veal2 KO, HUVEC permeability and rescue experiments","pmids":["34180064"],"confidence":"Medium","gaps":["Structural basis of VEAL2-DAG competition not resolved","Generality across PKCβ-dependent tissues untested"]},{"year":null,"claim":"How a single kinase achieves substrate, isoform, and subcellular selectivity across chromatin, mitochondria, plasma membrane, and organelles remains the central unresolved question.","evidence":"No single study integrates the scaffold (RACK1, TRPC3, PICK1) and RNA (VEAL2) targeting mechanisms with the full substrate repertoire","pmids":[],"confidence":"Low","gaps":["No unified model linking spatial targeting to substrate choice","Isoform-specific (βI vs βII) functional partitioning incompletely defined","Structural basis of most substrate recognitions unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,3,7,8,29,4,34,36]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[2,3,8,7,29]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[2,10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,14,33]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[18,37]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,10]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,7,25]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,6,26,37]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[18]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,10,35]}],"complexes":[],"partners":["RACK1","TRPC3","PICK1","RBCK1","PKD1","RIG-I","BTK"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05771","full_name":"Protein kinase C beta type","aliases":[],"length_aa":671,"mass_kda":76.9,"function":"Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity (PubMed:11598012). Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (AR)-dependent transcription, by being recruited to AR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A (PubMed:20228790). In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. Participates in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Phosphorylates SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1 (PubMed:25982116). Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis (By similarity). Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription (PubMed:19176525). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed:25313067). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231) Acts as an activator of ferroptosis by mediating phosphorylation and activation of ACSL4 (PubMed:35027735). Also stimulates ferroptosis propagation by catalyzing phosphorylation of FOXK1, thereby promoting LGALS13 secretion (PubMed:40246981)","subcellular_location":"Cytoplasm; Nucleus; Membrane","url":"https://www.uniprot.org/uniprotkb/P05771/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKCB","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRKCB","total_profiled":1310},"omim":[{"mim_id":"621219","title":"TRANSMEMBRANE PROTEIN 179; TMEM179","url":"https://www.omim.org/entry/621219"},{"mim_id":"615559","title":"AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3","url":"https://www.omim.org/entry/615559"},{"mim_id":"176977","title":"PROTEIN KINASE C, DELTA; PRKCD","url":"https://www.omim.org/entry/176977"},{"mim_id":"176970","title":"PROTEIN KINASE C, BETA; PRKCB","url":"https://www.omim.org/entry/176970"},{"mim_id":"156000","title":"MENIERE DISEASE","url":"https://www.omim.org/entry/156000"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":104.6},{"tissue":"lymphoid tissue","ntpm":44.0}],"url":"https://www.proteinatlas.org/search/PRKCB"},"hgnc":{"alias_symbol":["PKCβ"],"prev_symbol":["PRKCB2","PKCB","PRKCB1"]},"alphafold":{"accession":"P05771","domains":[{"cath_id":"3.30.60.20","chopping":"30-145","consensus_level":"high","plddt":88.7124,"start":30,"end":145},{"cath_id":"2.60.40.150","chopping":"159-288","consensus_level":"high","plddt":95.6052,"start":159,"end":288},{"cath_id":"3.30.200.20","chopping":"340-422_627-662","consensus_level":"high","plddt":88.4915,"start":340,"end":662},{"cath_id":"1.10.510.10","chopping":"425-609","consensus_level":"high","plddt":95.0155,"start":425,"end":609}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05771","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05771-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05771-F1-predicted_aligned_error_v6.png","plddt_mean":85.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKCB","jax_strain_url":"https://www.jax.org/strain/search?query=PRKCB"},"sequence":{"accession":"P05771","fasta_url":"https://rest.uniprot.org/uniprotkb/P05771.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05771/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05771"}},"corpus_meta":[{"pmid":"12118249","id":"PMC_12118249","title":"PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12118249","citation_count":264,"is_preprint":false},{"pmid":"20228790","id":"PMC_20228790","title":"Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20228790","citation_count":244,"is_preprint":false},{"pmid":"22826029","id":"PMC_22826029","title":"Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.","date":"2012","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/22826029","citation_count":182,"is_preprint":false},{"pmid":"23599343","id":"PMC_23599343","title":"A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts.","date":"2013","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/23599343","citation_count":162,"is_preprint":false},{"pmid":"9430559","id":"PMC_9430559","title":"Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531.","date":"1998","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/9430559","citation_count":130,"is_preprint":false},{"pmid":"11598012","id":"PMC_11598012","title":"PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11598012","citation_count":125,"is_preprint":false},{"pmid":"20685851","id":"PMC_20685851","title":"Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20685851","citation_count":120,"is_preprint":false},{"pmid":"16787950","id":"PMC_16787950","title":"PKCbeta-dependent activation of RhoA by syndecan-4 during focal adhesion formation.","date":"2006","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16787950","citation_count":110,"is_preprint":false},{"pmid":"20599775","id":"PMC_20599775","title":"The PKCbeta/HuR/VEGF pathway in diabetic retinopathy.","date":"2010","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20599775","citation_count":103,"is_preprint":false},{"pmid":"15920548","id":"PMC_15920548","title":"Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma.","date":"2005","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15920548","citation_count":102,"is_preprint":false},{"pmid":"12509514","id":"PMC_12509514","title":"Interaction of \"readthrough\" acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12509514","citation_count":102,"is_preprint":false},{"pmid":"22531062","id":"PMC_22531062","title":"IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCβ/Erk1/2/NF-κB-dependent signaling pathway.","date":"2012","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22531062","citation_count":102,"is_preprint":false},{"pmid":"22114345","id":"PMC_22114345","title":"Conventional protein kinase C-α (PKC-α) and PKC-β negatively regulate RIG-I antiviral signal transduction.","date":"2011","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/22114345","citation_count":99,"is_preprint":false},{"pmid":"12749884","id":"PMC_12749884","title":"Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.","date":"2003","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/12749884","citation_count":86,"is_preprint":false},{"pmid":"10452527","id":"PMC_10452527","title":"PKC-beta and PKC-zeta mediate opposing effects on proximal tubule Na+,K+-ATPase activity.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10452527","citation_count":83,"is_preprint":false},{"pmid":"23778835","id":"PMC_23778835","title":"PRKCB/protein kinase C, beta and the mitochondrial axis as key regulators of autophagy.","date":"2013","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/23778835","citation_count":81,"is_preprint":false},{"pmid":"27872094","id":"PMC_27872094","title":"MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27872094","citation_count":79,"is_preprint":false},{"pmid":"19168795","id":"PMC_19168795","title":"PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19168795","citation_count":72,"is_preprint":false},{"pmid":"10937586","id":"PMC_10937586","title":"PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10937586","citation_count":71,"is_preprint":false},{"pmid":"25808972","id":"PMC_25808972","title":"PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/25808972","citation_count":70,"is_preprint":false},{"pmid":"21892921","id":"PMC_21892921","title":"PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes.","date":"2012","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/21892921","citation_count":69,"is_preprint":false},{"pmid":"19036858","id":"PMC_19036858","title":"Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis.","date":"2008","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/19036858","citation_count":66,"is_preprint":false},{"pmid":"23766264","id":"PMC_23766264","title":"PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice.","date":"2013","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23766264","citation_count":61,"is_preprint":false},{"pmid":"21134959","id":"PMC_21134959","title":"Follow-up study identifies two novel susceptibility loci PRKCB and 8p11.21 for systemic lupus erythematosus.","date":"2010","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21134959","citation_count":60,"is_preprint":false},{"pmid":"20179100","id":"PMC_20179100","title":"Ca2+ influx and protein scaffolding via TRPC3 sustain PKCbeta and ERK activation in B cells.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/20179100","citation_count":59,"is_preprint":false},{"pmid":"33017608","id":"PMC_33017608","title":"Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKCβ/p66Shc axis and activation of FOXO-3a.","date":"2020","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33017608","citation_count":59,"is_preprint":false},{"pmid":"16027742","id":"PMC_16027742","title":"Haplotypes in the gene encoding protein kinase c-beta (PRKCB1) on chromosome 16 are associated with autism.","date":"2005","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16027742","citation_count":56,"is_preprint":false},{"pmid":"22930730","id":"PMC_22930730","title":"Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22930730","citation_count":56,"is_preprint":false},{"pmid":"15173888","id":"PMC_15173888","title":"PKCbeta regulates ischemia/reperfusion injury in the lung.","date":"2004","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15173888","citation_count":55,"is_preprint":false},{"pmid":"23963366","id":"PMC_23963366","title":"PKC-β exacerbates in vitro brain barrier damage in hyperglycemic settings via regulation of RhoA/Rho-kinase/MLC2 pathway.","date":"2013","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23963366","citation_count":54,"is_preprint":false},{"pmid":"28755662","id":"PMC_28755662","title":"Substrate stiffness governs the initiation of B cell activation by the concerted signaling of PKCβ and focal adhesion kinase.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28755662","citation_count":53,"is_preprint":false},{"pmid":"11287324","id":"PMC_11287324","title":"Increased contractility and altered Ca(2+) transients of mouse heart myocytes conditionally expressing PKCbeta.","date":"2001","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11287324","citation_count":51,"is_preprint":false},{"pmid":"27329761","id":"PMC_27329761","title":"A novel missense variant in PRKCB segregates low-frequency hearing loss in an autosomal dominant family with Meniere's disease.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27329761","citation_count":48,"is_preprint":false},{"pmid":"35576527","id":"PMC_35576527","title":"Thrombolytic tPA-induced hemorrhagic transformation of ischemic stroke is mediated by PKCβ phosphorylation of occludin.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35576527","citation_count":48,"is_preprint":false},{"pmid":"11299230","id":"PMC_11299230","title":"PKC-beta is not necessary for cardiac hypertrophy.","date":"2001","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11299230","citation_count":48,"is_preprint":false},{"pmid":"25001469","id":"PMC_25001469","title":"PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25001469","citation_count":46,"is_preprint":false},{"pmid":"12056801","id":"PMC_12056801","title":"Activation of PKC-beta isoforms mediates HNE-induced MCP-1 release by macrophages.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12056801","citation_count":46,"is_preprint":false},{"pmid":"34180064","id":"PMC_34180064","title":"LncRNA VEAL2 regulates PRKCB2 to modulate endothelial permeability in diabetic retinopathy.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/34180064","citation_count":45,"is_preprint":false},{"pmid":"19909372","id":"PMC_19909372","title":"Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19909372","citation_count":45,"is_preprint":false},{"pmid":"18245560","id":"PMC_18245560","title":"PKCbeta modulates ischemia-reperfusion injury in the heart.","date":"2008","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18245560","citation_count":44,"is_preprint":false},{"pmid":"10330050","id":"PMC_10330050","title":"Glycated albumin stimulation of PKC-beta activity is linked to increased collagen IV in mesangial cells.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10330050","citation_count":43,"is_preprint":false},{"pmid":"25568344","id":"PMC_25568344","title":"GPCR-mediated PLCβγ/PKCβ/PKD signaling pathway regulates the cofilin phosphatase slingshot 2 in neutrophil chemotaxis.","date":"2015","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/25568344","citation_count":42,"is_preprint":false},{"pmid":"18412141","id":"PMC_18412141","title":"Epstein-Barr virus latent membrane protein 1 mediates serine 25 phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKCalpha/PKCbeta pathway.","date":"2008","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18412141","citation_count":41,"is_preprint":false},{"pmid":"25454347","id":"PMC_25454347","title":"Increased extracellular pressure stimulates tumor proliferation by a mechanosensitive calcium channel and PKC-β.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25454347","citation_count":41,"is_preprint":false},{"pmid":"19929710","id":"PMC_19929710","title":"Ruboxistaurin: PKC-beta inhibition for complications of diabetes.","date":"2009","source":"Expert opinion on pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/19929710","citation_count":40,"is_preprint":false},{"pmid":"23824069","id":"PMC_23824069","title":"PKCβ phosphorylates PI3Kγ to activate it and release it from GPCR control.","date":"2013","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/23824069","citation_count":40,"is_preprint":false},{"pmid":"26936881","id":"PMC_26936881","title":"Usp9X Is Required for Lymphocyte Activation and Homeostasis through Its Control of ZAP70 Ubiquitination and PKCβ Kinase Activity.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26936881","citation_count":39,"is_preprint":false},{"pmid":"17044810","id":"PMC_17044810","title":"Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.","date":"2006","source":"Expert opinion on drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/17044810","citation_count":37,"is_preprint":false},{"pmid":"20875828","id":"PMC_20875828","title":"Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation.","date":"2010","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20875828","citation_count":37,"is_preprint":false},{"pmid":"20044781","id":"PMC_20044781","title":"A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats.","date":"2010","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/20044781","citation_count":35,"is_preprint":false},{"pmid":"15252133","id":"PMC_15252133","title":"The receptor for activated C-kinase-I (RACK-I) anchors activated PKC-beta on melanosomes.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15252133","citation_count":35,"is_preprint":false},{"pmid":"20079359","id":"PMC_20079359","title":"A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats.","date":"2010","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/20079359","citation_count":35,"is_preprint":false},{"pmid":"31689616","id":"PMC_31689616","title":"hsa_circ_0092306 Targeting miR-197-3p Promotes Gastric Cancer Development by Regulating PRKCB in MKN-45 Cells.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31689616","citation_count":34,"is_preprint":false},{"pmid":"24912759","id":"PMC_24912759","title":"Up-regulated HMGB1 in EAM directly led to collagen deposition by a PKCβ/Erk1/2-dependent pathway: cardiac fibroblast/myofibroblast might be another source of HMGB1.","date":"2014","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24912759","citation_count":32,"is_preprint":false},{"pmid":"26996926","id":"PMC_26996926","title":"PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.","date":"2016","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26996926","citation_count":30,"is_preprint":false},{"pmid":"8071613","id":"PMC_8071613","title":"Expression of protein kinase C isozymes in guinea pig epidermis: selective inhibition of PKC-beta activity by 13-hydroxyoctadecadienoic acid-containing diacylglycerol.","date":"1994","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/8071613","citation_count":30,"is_preprint":false},{"pmid":"24930012","id":"PMC_24930012","title":"Blockade of PKCβ protects against remote organ injury induced by intestinal ischemia and reperfusion via a p66shc-mediated mitochondrial apoptotic pathway.","date":"2014","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/24930012","citation_count":30,"is_preprint":false},{"pmid":"11707282","id":"PMC_11707282","title":"A PKCbeta isoform mediates phorbol ester-induced activation of Erk1/2 and expression of neuronal differentiation genes in neuroblastoma cells.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11707282","citation_count":29,"is_preprint":false},{"pmid":"18996181","id":"PMC_18996181","title":"The ability of Listeria monocytogenes PI-PLC to facilitate escape from the macrophage phagosome is dependent on host PKCbeta.","date":"2008","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18996181","citation_count":29,"is_preprint":false},{"pmid":"32929374","id":"PMC_32929374","title":"circ-PRKCB acts as a ceRNA to regulate p66Shc-mediated oxidative stress in intestinal ischemia/reperfusion.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32929374","citation_count":28,"is_preprint":false},{"pmid":"11478844","id":"PMC_11478844","title":"Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption.","date":"2001","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11478844","citation_count":28,"is_preprint":false},{"pmid":"12874455","id":"PMC_12874455","title":"Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-beta1 (PRKCB1) gene locus.","date":"2003","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/12874455","citation_count":27,"is_preprint":false},{"pmid":"24136171","id":"PMC_24136171","title":"Role of PKC-β in chemical allergen-induced CD86 expression and IL-8 release in THP-1 cells.","date":"2013","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/24136171","citation_count":27,"is_preprint":false},{"pmid":"32048876","id":"PMC_32048876","title":"Intermittent Hypoxia Augments Pulmonary Vasoconstrictor Reactivity through PKCβ/Mitochondrial Oxidant Signaling.","date":"2020","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32048876","citation_count":26,"is_preprint":false},{"pmid":"10209302","id":"PMC_10209302","title":"Effect of tumor necrosis factor-alpha on insulin signal transduction in rat adipocytes: relation to PKCbeta and zeta translocation.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10209302","citation_count":26,"is_preprint":false},{"pmid":"25436907","id":"PMC_25436907","title":"Reversible blockade of complex I or inhibition of PKCβ reduces activation and mitochondria translocation of p66Shc to preserve cardiac function after ischemia.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25436907","citation_count":25,"is_preprint":false},{"pmid":"20029385","id":"PMC_20029385","title":"Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/20029385","citation_count":25,"is_preprint":false},{"pmid":"19825373","id":"PMC_19825373","title":"Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.","date":"2009","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/19825373","citation_count":25,"is_preprint":false},{"pmid":"28476069","id":"PMC_28476069","title":"ELAC (3,12-di-O-acetyl-8-O-tigloilingol), a plant-derived lathyrane diterpene, induces subventricular zone neural progenitor cell proliferation through PKCβ activation.","date":"2017","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28476069","citation_count":24,"is_preprint":false},{"pmid":"16567829","id":"PMC_16567829","title":"Polymorphisms of the protein kinase C-beta gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria.","date":"2006","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/16567829","citation_count":23,"is_preprint":false},{"pmid":"16281914","id":"PMC_16281914","title":"Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-beta, -eta and -zeta) in a rat model of cerebral basilar artery vasospasm.","date":"2005","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/16281914","citation_count":23,"is_preprint":false},{"pmid":"27624939","id":"PMC_27624939","title":"Novel Insights into the PKCβ-dependent Regulation of the Oxidoreductase p66Shc.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27624939","citation_count":23,"is_preprint":false},{"pmid":"15662033","id":"PMC_15662033","title":"Central role of PKCbeta in neointimal expansion triggered by acute arterial injury.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15662033","citation_count":23,"is_preprint":false},{"pmid":"34198725","id":"PMC_34198725","title":"Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34198725","citation_count":22,"is_preprint":false},{"pmid":"25256217","id":"PMC_25256217","title":"PKCβ positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3β.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/25256217","citation_count":22,"is_preprint":false},{"pmid":"38382281","id":"PMC_38382281","title":"Schisandrin A alleviates renal fibrosis by inhibiting PKCβ and oxidative stress.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38382281","citation_count":22,"is_preprint":false},{"pmid":"25982096","id":"PMC_25982096","title":"Homocysteine facilitates LOX-1 activation and endothelial death through the PKCβ and SIRT1/HSF1 mechanism: relevance to human hyperhomocysteinaemia.","date":"2015","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/25982096","citation_count":22,"is_preprint":false},{"pmid":"30153408","id":"PMC_30153408","title":"Single Quantum Dot Imaging Reveals PKCβ-Dependent Alterations in Membrane Diffusion and Clustering of an Attention-Deficit Hyperactivity Disorder/Autism/Bipolar Disorder-Associated Dopamine Transporter Variant.","date":"2018","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30153408","citation_count":22,"is_preprint":false},{"pmid":"34395424","id":"PMC_34395424","title":"P2X7 Receptor Deficiency Ameliorates STZ-induced Cardiac Damage and Remodeling Through PKCβ and ERK.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34395424","citation_count":21,"is_preprint":false},{"pmid":"21803871","id":"PMC_21803871","title":"Role for PKCβ in enhanced endothelin-1-induced pulmonary vasoconstrictor reactivity following intermittent hypoxia.","date":"2011","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21803871","citation_count":21,"is_preprint":false},{"pmid":"23457506","id":"PMC_23457506","title":"IL-33 attenuates anoxia/reoxygenation-induced cardiomyocyte apoptosis by inhibition of PKCβ/JNK pathway.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23457506","citation_count":21,"is_preprint":false},{"pmid":"28414198","id":"PMC_28414198","title":"LY333531, a PKCβ inhibitor, attenuates glomerular endothelial cell apoptosis in the early stage of mouse diabetic nephropathy via down-regulating swiprosin-1.","date":"2017","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/28414198","citation_count":21,"is_preprint":false},{"pmid":"10801269","id":"PMC_10801269","title":"Murine colonic mucosa hyperproliferation. II. PKC-beta activation and cPKC-mediated cellular CFTR overexpression.","date":"2000","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10801269","citation_count":20,"is_preprint":false},{"pmid":"17313671","id":"PMC_17313671","title":"Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas.","date":"2007","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/17313671","citation_count":20,"is_preprint":false},{"pmid":"21864610","id":"PMC_21864610","title":"PKCβ-dependent phosphorylation of the glycine transporter 1.","date":"2011","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/21864610","citation_count":19,"is_preprint":false},{"pmid":"18759374","id":"PMC_18759374","title":"Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.","date":"2009","source":"Hematological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18759374","citation_count":19,"is_preprint":false},{"pmid":"11443050","id":"PMC_11443050","title":"Negative regulation of ligand-initiated Ca(2+) uptake by PKC-beta II in differentiated HL60 cells.","date":"2001","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11443050","citation_count":19,"is_preprint":false},{"pmid":"15473137","id":"PMC_15473137","title":"Protein kinase C (PKC) beta modulates serine phosphorylation of insulin receptor substrate-1 (IRS-1)--effect of overexpression of PKCbeta on insulin signal transduction.","date":"2004","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/15473137","citation_count":19,"is_preprint":false},{"pmid":"17121852","id":"PMC_17121852","title":"RBCK1, a protein kinase CbetaI (PKCbetaI)-interacting protein, regulates PKCbeta-dependent function.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17121852","citation_count":18,"is_preprint":false},{"pmid":"11894137","id":"PMC_11894137","title":"Lack of protein kinase C (PKC)-beta and low PKC-alpha, -delta, -epsilon, and -zeta isozyme levels in proliferating human melanoma cells.","date":"2002","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11894137","citation_count":18,"is_preprint":false},{"pmid":"31175056","id":"PMC_31175056","title":"Hyper-methylation of AVPR1A and PKCΒ gene associated with insensitivity to arginine vasopressin in human pre-eclamptic placental vasculature.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31175056","citation_count":18,"is_preprint":false},{"pmid":"16564096","id":"PMC_16564096","title":"Selective role of PKCbeta enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking.","date":"2006","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/16564096","citation_count":18,"is_preprint":false},{"pmid":"30417389","id":"PMC_30417389","title":"The PKCβ-p66shc-NADPH oxidase pathway plays a crucial role in diabetic nephropathy.","date":"2018","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30417389","citation_count":18,"is_preprint":false},{"pmid":"27150838","id":"PMC_27150838","title":"SLA-PGN-primed dendritic cell-based vaccination induces Th17-mediated protective immunity against experimental visceral leishmaniasis: a crucial role of PKCβ.","date":"2016","source":"Pathogens and disease","url":"https://pubmed.ncbi.nlm.nih.gov/27150838","citation_count":18,"is_preprint":false},{"pmid":"32290846","id":"PMC_32290846","title":"Chronic morphine regulates TRPM8 channels via MOR-PKCβ signaling.","date":"2020","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/32290846","citation_count":17,"is_preprint":false},{"pmid":"18339533","id":"PMC_18339533","title":"Surface plasmon resonance biosensor detects the downstream events of active PKCbeta in antigen-stimulated mast cells.","date":"2008","source":"Biosensors & bioelectronics","url":"https://pubmed.ncbi.nlm.nih.gov/18339533","citation_count":17,"is_preprint":false},{"pmid":"14985314","id":"PMC_14985314","title":"Effect of PKCbeta on retinal oxygenation response in experimental diabetes.","date":"2004","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/14985314","citation_count":17,"is_preprint":false},{"pmid":"18211822","id":"PMC_18211822","title":"Activation of PKCbeta(II) and PKCtheta is essential for LDL-induced cell proliferation of human aortic smooth muscle cells via Gi-mediated Erk1/2 activation and Egr-1 upregulation.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18211822","citation_count":17,"is_preprint":false},{"pmid":"26540567","id":"PMC_26540567","title":"Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26540567","citation_count":17,"is_preprint":false},{"pmid":"33085045","id":"PMC_33085045","title":"PKCβ/NF-κB pathway in diabetic atrial remodeling.","date":"2020","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33085045","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52480,"output_tokens":9734,"usd":0.151725,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20629,"output_tokens":3964,"usd":0.101123,"stage2_stop_reason":"end_turn"},"total_usd":0.252848,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"PKCβ is specifically required for BCR-mediated NF-κB activation; PKCβ-deficient B cells fail to recruit the IKK complex into lipid rafts, activate IKK, or degrade IκB, placing PKCβ upstream of IKK in the BCR survival signaling pathway.\",\n      \"method\": \"PKCβ knockout mice, lipid raft fractionation, IKK activity assays, IκB degradation assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal biochemical readouts (raft fractionation, IKK activation, IκB degradation), replicated in pharmacological inhibition studies\",\n      \"pmids\": [\"12118249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PKCβ acts as a feedback inhibitor of Btk activation by phosphorylating a conserved serine in the Tec homology domain linker of Btk; mutation of this site enhances Btk tyrosine phosphorylation, membrane association, and augmented BCR/FcεRI-mediated signaling.\",\n      \"method\": \"PKCβ knockout mice, site-directed mutagenesis of Btk phosphorylation site, Ca2+ signaling assays, membrane fractionation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis of identified phosphorylation site combined with KO mouse and functional signaling readouts\",\n      \"pmids\": [\"11598012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PKCβI phosphorylates histone H3 at threonine 6 (H3T6ph) during androgen receptor (AR)-dependent gene activation, preventing LSD1 from demethylating H3K4 (but not H3K9), thereby writing a new chromatin mark that maintains active methylation states. PKCβI is recruited to AR target gene promoters after androgen stimulation, requiring prior activation by the gatekeeper kinase PRK1.\",\n      \"method\": \"In vitro histone peptide LSD1 demethylation assays, ChIP, RNAi knockdown, in vivo tumor xenograft, in vitro kinase assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, mutagenesis-equivalent peptide assay, ChIP, RNAi with rescue, and in vivo xenograft in one study\",\n      \"pmids\": [\"20228790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In differentiated osteoclasts, RANKL activates PKCβ, which phosphorylates the transcription factor TFEB on three serine residues in its C-terminal 15 amino acids, stabilizing and activating TFEB to promote lysosomal biogenesis necessary for bone resorption.\",\n      \"method\": \"Cell-based phosphorylation assays, osteoclast-specific gene deletion in mice, cell size/lysosomal gene expression assays, Western blot\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — biochemical phosphorylation mapping combined with conditional KO in mice and multiple cellular readouts\",\n      \"pmids\": [\"23599343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PKCβ phosphorylates Ser582 in the helical domain of the PI3Kγ catalytic subunit p110γ in response to FcεRI clustering and/or store-operated Ca2+ influx in mast cells, correlating with release of the p84 adapter subunit from the p84-p110γ complex and increased p110γ activity, thereby disconnecting PI3Kγ from its canonical GPCR inputs.\",\n      \"method\": \"In vitro kinase assay, phospho-mimicking mutagenesis, Co-IP, hydrogen-deuterium exchange mass spectrometry, PKCβ knockout cells\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — phosphorylation site identified with kinase assay, phospho-mimetic mutagenesis, HDX-MS structural analysis, and KO validation\",\n      \"pmids\": [\"23824069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RACK1 anchors activated PKCβ specifically on melanosome membranes, allowing PKCβ (but not PKCα) to phosphorylate tyrosinase on specific serine residues on its cytoplasmic domain, activating melanogenesis. Disruption of RACK1-PKCβ interaction with DECA or siRNA knockdown of RACK1 decreases tyrosinase activity.\",\n      \"method\": \"Melanosome purification, co-immunoprecipitation, siRNA knockdown of RACK1, tyrosinase activity assays, DECA pharmacological disruption\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP from purified organelle fraction, siRNA knockdown, pharmacological disruption, and functional enzyme assay\",\n      \"pmids\": [\"15252133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In B cells, TRPC3 serves as both a Ca2+-permeable channel and a direct protein scaffold for PKCβ at the plasma membrane; TRPC3 deficiency impairs DAG-activated Ca2+ currents and the sustained BCR-stimulated translocation of PKCβ to the plasma membrane, preventing downstream ERK activation.\",\n      \"method\": \"TRPC3-deficient DT40 B cells, electrophysiology, PKCβ translocation imaging, Co-IP (direct PKCβ-TRPC3 association), ERK activation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with direct protein-protein interaction (Co-IP) and functional signaling readouts\",\n      \"pmids\": [\"20179100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PKCα and PKCβ phosphorylate RIG-I at S8 and T170, suppressing TRIM25 binding and K63-linked ubiquitination of RIG-I, thereby negatively regulating RIG-I antiviral IFN signaling under normal conditions. PKCα/β interact with RIG-I under normal (unstimulated) conditions.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis of RIG-I S8/T170, gene silencing, pharmacological inhibition, IFN induction assays, VSV infection resistance assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutagenesis, Co-IP, siRNA knockdown, and inhibitor treatment with multiple orthogonal functional assays\",\n      \"pmids\": [\"22114345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"tPA activates PKCβ, which phosphorylates occludin at serine 490 (S490) in the ischemic penumbra, increasing cerebrovascular permeability and the risk of hemorrhagic transformation. Blocking S490 phosphorylation with a non-phosphorylatable occludin (S490A) or PKCβ inhibition reduces permeability and intracerebral hemorrhage.\",\n      \"method\": \"Mouse MCAO model (tPA-/- mice), intraventricular tPA injection, S490A occludin knock-in, PKCβ pharmacological inhibition, permeability assays, Western blot\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (KO mice, non-phosphorylatable mutant) and pharmacological approaches with multiple in vivo functional readouts\",\n      \"pmids\": [\"35576527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"H2O2 activates a PKCβ/p66Shc/NF-κB signaling cascade in osteoblastic cells; p66Shc is an essential mediator of H2O2-induced apoptosis and NF-κB activation downstream of PKCβ. Estrogens and androgens attenuate these effects by suppressing PKCβ phosphorylation via a non-nuclear (membrane-initiated) mechanism.\",\n      \"method\": \"H2O2 treatment of mesenchymal/osteoblastic cell models, siRNA knockdown of p66Shc, polymeric estradiol (non-nuclear ER action), Western blot, apoptosis assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis and pharmacological approaches in a single lab with two orthogonal methods (knockdown + non-nuclear estradiol)\",\n      \"pmids\": [\"20685851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PRKCB (PKCβ) phosphorylates histone H3T6 to globally maintain H3K4 trimethylation at gene promoters in Ewing sarcoma cells; transcriptional activation of PRKCB is directly regulated by the EWSR1-FLI1 chimeric oncogene. PRKCB loss induces apoptosis in vitro and prevents tumor growth in vivo.\",\n      \"method\": \"Gene expression profiling, ChIP for H3T6ph/H3K4me3, siRNA/shRNA knockdown of PRKCB, in vivo xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and gene expression profiling with KD/KO phenotype, single lab\",\n      \"pmids\": [\"22930730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PKCβ activates HuR (ELAV protein) via phosphorylation in the diabetic retina, increasing HuR binding to VEGF mRNA and stabilizing it, leading to enhanced VEGF protein expression. PKCβ inhibition blocks this PKCβ/HuR/VEGF pathway.\",\n      \"method\": \"Streptozotocin diabetic rat model, immunoprecipitation/RT-PCR (RNP complexes), PKCβ inhibitor treatment, Western blot for HuR phosphorylation\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNP immunoprecipitation with RT-PCR showing direct HuR-VEGF mRNA interaction, inhibitor treatment, single lab\",\n      \"pmids\": [\"20599775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PKCβ activation induced by diabetes decreases GLP-1 receptor (GLP-1R) expression in glomerular endothelial cells by increasing its ubiquitination-dependent degradation and enhancing phospho-c-Raf(Ser338)/ERK1/2 activation by angiotensin II.\",\n      \"method\": \"EC-PKCβ2 transgenic mice, siRNA knockdown of GLP-1R, Western blot, ubiquitination assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse model plus siRNA with biochemical mechanistic endpoint (ubiquitination), single lab\",\n      \"pmids\": [\"22826029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PKCβ activates the RhoA/Rho-kinase/MLC2 pathway in brain microvascular endothelial cells exposed to high glucose, leading to decreased occludin expression, cytoskeletal changes, and blood-brain barrier dysfunction.\",\n      \"method\": \"siRNA knockdown of PKCβ, PKCβ inhibitor (LY333531), transendothelial electrical resistance, FITC-dextran permeability, Rho activity assays, Western blot\",\n      \"journal\": \"Journal of cerebral blood flow and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological inhibition with pathway positioning (PKCβ → RhoA/ROCK/MLC2), single lab\",\n      \"pmids\": [\"23963366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PKCβ activation in osteoblastic cells mediates PTH-, TNF-α-, and IL-1β-stimulated IL-6 promoter activation and PTH-stimulated bone resorption; PTH/TNF-α/IL-1β induces translocation of PKCβI (but not PKCα) to the plasma membrane, and this translocation is blocked by a selective PKCβ antagonist (LY379196).\",\n      \"method\": \"PKCβ translocation assays, IL-6 promoter-luciferase reporter, selective PKCβ inhibitor (LY379196), fetal rat bone organ culture resorption assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibition with reporter assay and ex vivo bone resorption, single lab, multiple readouts\",\n      \"pmids\": [\"11478844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PKCβ-dependent activation of FAK is required for B cell mechanosensing; PMA-induced PKCβ activation can bypass Btk and PLCγ2 to activate FAK, which potentiates B cell spreading and adhesion. FAK inactivation or deficiency impairs B cell discrimination of substrate stiffness.\",\n      \"method\": \"PKCβ pharmacological activation (PMA), FAK inhibitor/KO, B cell spreading assays on substrates of varying stiffness, signaling Western blots\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis (PKCβ bypasses Btk/PLCγ2 to activate FAK), FAK KO confirmation, multiple substrate stiffness conditions\",\n      \"pmids\": [\"28755662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RBCK1 binds PKCβI and is a key regulator of PKCβI function in cardiac myocytes; RBCK1 overexpression induces cardiac cell hypertrophy in a PKCβ-dependent manner, and RNAi of RBCK1 inhibits phenylephrine-induced hypertrophy. RBCK1 association with PKCβI increases transiently upon phenylephrine stimulation.\",\n      \"method\": \"Co-immunoprecipitation, adenoviral RBCK1 overexpression, siRNA knockdown of RBCK1, PKCβ-selective antagonist treatment, cardiomyocyte cell size measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, siRNA and OE epistasis, PKCβ inhibitor rescue, single lab\",\n      \"pmids\": [\"17121852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PKCβ mediates PMA-dependent stimulation of Na+,K+-ATPase in proximal tubule cells, while PKCζ mediates dopamine-dependent inhibition; these two isoforms exert opposing effects on Na+,K+-ATPase activity, as demonstrated with isoform-specific inhibitor peptides and LY333531.\",\n      \"method\": \"Isoform-specific PKC inhibitor peptides, LY333531 (PKCβ inhibitor), Na+,K+-ATPase activity assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific inhibitory peptides and pharmacological inhibition with functional enzyme assay, single lab\",\n      \"pmids\": [\"10452527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PRKCB (PKCβ) activation negatively modulates mitochondrial membrane potential and inhibits autophagy; pharmacological PRKCB inhibition and PRKCB knockout MEFs show increased autophagy and increased mitochondrial membrane potential, placing PRKCB upstream of mitochondrial energy status in the regulation of autophagy.\",\n      \"method\": \"PKCβ pharmacological inhibitor, prkcb knockout MEFs, autophagy flux assays, mitochondrial membrane potential measurements\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition with functional autophagy and mitochondrial readouts, single lab\",\n      \"pmids\": [\"23778835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PKCβ mediates MIF-induced IL-8 production in bone marrow mesenchymal stromal cells via MIF receptor CD74; this IL-8 supports AML blast survival, placing PKCβ in a MIF→CD74→PKCβ→IL-8 stromal signaling axis.\",\n      \"method\": \"Recombinant MIF treatment, MIF inhibitor (ISO-1), PKCβ inhibitor, co-culture assays, cytokine ELISA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological epistasis positioning PKCβ downstream of CD74/MIF, functional IL-8/survival readouts, single lab\",\n      \"pmids\": [\"27872094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PKCβ contributes to lung ischemia/reperfusion injury by coordinated activation of ERK1/2 and JNK MAPKs and induction of Egr-1 (early growth response-1) and its downstream target genes, particularly in mononuclear phagocytes; PKCβ null mice and ruboxistaurin treatment reduce these responses and improve survival.\",\n      \"method\": \"PKCβ knockout mice, ruboxistaurin pharmacological inhibition, murine single-lung I/R model, MAPK phosphorylation Western blots, Egr-1 expression assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition, multiple molecular readouts, single lab\",\n      \"pmids\": [\"15173888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PKCβII mediates myocardial ischemia/reperfusion injury at least in part via JNK phosphorylation and caspase-3 activation; PKCβ null mice and ruboxistaurin treatment show decreased infarct size, improved LV function, and reduced JNK phosphorylation/caspase-3 activation.\",\n      \"method\": \"PKCβ knockout mice, ruboxistaurin treatment, coronary artery occlusion/reperfusion model, JNK/caspase-3 Western blots, infarct size measurement\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition with mechanistic pathway (PKCβ→JNK→caspase-3), single lab\",\n      \"pmids\": [\"18245560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PKCβ is required for neointimal expansion after acute arterial injury; PKCβII regulates vascular smooth muscle cell migration and proliferation, at least in part via ERK1/2 MAPK and Egr-1 transcription factor activation.\",\n      \"method\": \"PKCβ knockout mice, ruboxistaurin treatment, femoral artery denudation injury model, ERK1/2 and Egr-1 expression assays, in vitro SMC assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition with in vivo and in vitro mechanistic readouts, single lab\",\n      \"pmids\": [\"15662033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PKCβII activation in aortic endothelial cells is a critical upstream regulator of Egr-1 and MMP-2 in response to oxLDL via a PKCβ-JNK MAPK pathway; loss of PKCβ in apoE-/- mice reduces atherosclerotic lesion area with concomitant reductions in Egr-1 and MMP-2.\",\n      \"method\": \"PKCβ/apoE double-KO mice, ruboxistaurin pharmacological inhibition, primary endothelial cell PKCβ/JNK inhibitor experiments, MMP-2 activity assays, lesion quantification\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double-KO mice with multiple mechanistic endpoints, single lab\",\n      \"pmids\": [\"19036858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PKCβ activation in diabetes reduces IL-18BP expression in endothelial cells, leading to unrestrained IL-18 signaling, VCAM-1 upregulation, and increased monocyte adhesion; siRNA, ruboxistaurin, and IL-18 neutralizing antibody each prevent elevated VCAM-1 and monocyte adherence.\",\n      \"method\": \"ApoE-/- diabetic mouse model with ruboxistaurin, siRNA knockdown of PKCβ/GLP-1R, EC/macrophage high-glucose treatment, monocyte adhesion assays, VCAM-1 Western blot\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological inhibition with in vivo and in vitro functional readouts, single lab\",\n      \"pmids\": [\"25808972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Usp9X is required for induction of PKCβ kinase activity after BCR-dependent activation in B lymphocytes; in Usp9X knockout B cells, PKCβ activity is reduced, leading to decreased CARMA1 phosphorylation, reduced CARMA1/Bcl-10/MALT-1 complex formation, and impaired NF-κB-dependent cell survival.\",\n      \"method\": \"Usp9X conditional knockout mice, BCR stimulation, CARMA1 phosphorylation/complex assays, NF-κB reporter, B cell survival assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with multiple downstream biochemical readouts placing Usp9X→PKCβ→CARMA1→NF-κB, single lab\",\n      \"pmids\": [\"26936881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PKCβ specifically interacts with and activates PKD1 in GPCR-stimulated neutrophils; PKCβ-PKD1 interaction and signaling are required for GPCR-mediated phosphorylation of the cofilin phosphatase SSH2, actin cytoskeletal reorganization, and neutrophil chemotaxis.\",\n      \"method\": \"Co-IP of PKCβ-PKD1, siRNA knockdown, pharmacological inhibition, neutrophil chemotaxis assays, cofilin phosphorylation assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct PKCβ-PKD1 Co-IP plus functional chemotaxis assay with siRNA epistasis, single lab\",\n      \"pmids\": [\"25568344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PKCβ phosphorylates glycine transporter 1 (GlyT1) on serine/threonine residues (not tyrosine); while classical PKCα/β regulate GlyT1 uptake, PKCβ-specific inhibitors selectively block GlyT1 phosphorylation without affecting glycine uptake, suggesting distinct roles for PKCα versus PKCβ in GlyT1 regulation.\",\n      \"method\": \"[32P]-orthophosphate metabolic labeling, isoform-selective PKC inhibitors (Gö6976, LY333531), glycine uptake assays in stably-transfected cells\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct phosphorylation labeling with isoform-selective inhibitors and functional transport assays, single lab\",\n      \"pmids\": [\"21864610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Conditional expression of PKCβ in cardiac myocytes increases peak Ca2+ transient amplitude, extent and rate of shortening, and rate of relengthening, without altering phospholamban phosphorylation or SR Ca2+ uptake rates; at 10 months, maximum tension is depressed with increased myofilament protein phosphorylation.\",\n      \"method\": \"Transgenic mouse model with conditional PKCβ expression, Ca2+ transient measurements, sarcomere shortening assays, SR vesicle Ca2+-uptake assays, skinned fiber mechanics, Western blot\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional transgenic with multiple functional cardiac readouts, single lab\",\n      \"pmids\": [\"11287324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PKCβ-mediated phosphorylation of p66Shc occurs at Ser139 and Ser213 (not Ser36 as previously proposed), regulating p66Shc pro-oxidant and pro-apoptotic function; phosphomimetic mutation of Thr206 and Ser213 produces gain-of-function with increased ROS and cell death.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis of p66Shc phosphorylation sites, ROS measurements, cell death assays, PKCβ knockout cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro phosphorylation assay with mutagenesis and functional ROS/apoptosis readouts, single lab; CONTRADICTS prior Ser36 claim\",\n      \"pmids\": [\"27624939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PKCβ activation mediates HNE (4-hydroxynonenal)-induced MCP-1 release from murine macrophages, a distinct mechanism from LPS-induced MCP-1 secretion (which involves PKCδ).\",\n      \"method\": \"PKC isoform activity assays, pharmacological PKC inhibitors, MCP-1 ELISA in macrophages\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibition with a single functional readout (MCP-1), single lab, no direct PKCβ-target interaction shown\",\n      \"pmids\": [\"12056801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Listeria monocytogenes PI-PLC promotes escape from the macrophage phagosome by generating diacylglycerol that activates host PKCβ; in PKCβ knockout macrophages, Listeria uses a PC-PLC-dependent (PKCβ-independent) pathway instead, demonstrating that PI-PLC-facilitated escape specifically requires host PKCβ.\",\n      \"method\": \"PKCβ knockout bone marrow-derived macrophages, bacterial escape assays, PI-PLC and PC-PLC mutant Listeria strains\",\n      \"journal\": \"Microbial pathogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with bacterial mutants defining a specific pathway (PI-PLC→DAG→PKCβ for phagosome escape), single lab\",\n      \"pmids\": [\"18996181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Stress-induced AChE-R splice variant interacts intraneuronally with the scaffold protein RACK1, and through RACK1, with PKCβII in stress-responsive brain regions; elevated AChE-R is associated with increased RACK1/PKCβII co-localization and prolonged fear-induced behavioral inhibition.\",\n      \"method\": \"Co-immunoprecipitation of RACK1-PKCβII, antisense prevention of AChE-R, transgenic mice overexpressing AChE-R, immunohistochemistry, open-field behavioral testing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and transgenic model with functional behavioral readout, single lab\",\n      \"pmids\": [\"12509514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Glycated albumin (Amadori-modified) activates PKCβ (specifically PKCβ1 membrane translocation) in glomerular mesangial cells under physiological glucose concentrations, and this PKCβ activation is causally linked to increased collagen type IV production, as demonstrated by beta-specific PKC inhibitors.\",\n      \"method\": \"PKCβ-specific inhibitor (LY-379196), PKCβ1 membrane fractionation, PKC activity assay, collagen IV production assay\",\n      \"journal\": \"The American journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibition with isoform-specific compound and membrane translocation assay, functional collagen readout, single lab\",\n      \"pmids\": [\"10330050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Chronic morphine activates MOR-PLC-PKCβ signaling, which phosphorylates TRPM8 at consensus PKC sites S1040 and S1041; this reduces TRPM8 desensitization and promotes TRPM8 hyperexcitability and cold hyperalgesia. Site-directed mutation of S1040/S1041 prevents MOR-induced TRPM8 desensitization reduction.\",\n      \"method\": \"Site-directed mutagenesis of TRPM8 S1040/S1041, PKCβ pharmacological inhibition, DRG neuronal electrophysiology, cold hyperalgesia behavioral assays in mice\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis of phosphorylation sites with functional channel desensitization assays and in vivo behavioral confirmation, single lab\",\n      \"pmids\": [\"32290846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PKCβ positively regulates RANKL-induced osteoclastogenesis by phosphorylating and inactivating GSK-3β, leading to NFATc1 induction. PKCβ expression increases in response to RANKL, and pharmacological or siRNA inhibition of PKCβ suppresses GSK-3β phosphorylation, NFATc1, and osteoclast differentiation.\",\n      \"method\": \"PKCβ pharmacological inhibition, siRNA knockdown, GSK-3β phosphorylation Western blot, NFATc1 induction assays, RANKL-injected mouse calvaria model\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological epistasis identifying PKCβ→GSK-3β→NFATc1 axis, in vivo confirmation, single lab\",\n      \"pmids\": [\"25256217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PKCβ mediates serine phosphorylation of IRS-1 in adipocytes; overexpression of PKCβ induces IRS-1 mobility shift and serine phosphorylation and decreases insulin-stimulated glucose uptake, while dominant-negative PKCβ blocks these effects and enhances glucose uptake.\",\n      \"method\": \"In vitro PKC phosphorylation of immunoprecipitated IRS-1, PKCβ overexpression and dominant-negative PKCβ in adipocytes, 2-DOG uptake assays, Western blot\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay with functional overexpression/dominant-negative epistasis, single lab\",\n      \"pmids\": [\"15473137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PKCβ mediates pulmonary vasoconstriction through interaction with the scaffolding protein PICK1 at mitochondria; PKCβ acutely translocates to mitochondria upon stimulation and activates mitoKATP channels, leading to mitochondrial ROS generation that drives vasoconstriction and pulmonary hypertension after intermittent hypoxia.\",\n      \"method\": \"Subcellular fractionation, proximity ligation assay (PKCβ-PICK1), mitoKATP inhibitors, antioxidant/PKCβ inhibitor in vivo, PKCβ inhibitor LY-333531, pulmonary artery contractility assays\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity ligation for PKCβ-PICK1 interaction, subcellular fractionation showing mitochondrial translocation, functional vasoconstriction assay with pharmacological inhibition, single lab\",\n      \"pmids\": [\"32048876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"lncRNA VEAL2 competes with diacylglycerol for binding to PRKCB2 and regulates its kinase activity; VEAL2 overexpression and knockdown modulate endothelial tubulogenesis and permeability, and VEAL2 can rescue PRKCB2-mediated turnover of junctional proteins.\",\n      \"method\": \"VEAL2 pulldown using PRKCB2 as bait, zebrafish veal2 knockout (cranial hemorrhage), HUVEC overexpression/knockdown, kinase activity assays, hyperglycemic HUVEC model\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein-RNA interaction with PRKCB2 bait, kinase activity assay, zebrafish KO phenotype, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34180064\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKCB (PKCβ) is a diacylglycerol/Ca2+-activated serine/threonine kinase that phosphorylates diverse substrates to regulate B cell receptor signaling (inhibiting Btk membrane localization and activating NF-κB via IKK lipid raft recruitment), chromatin state (writing H3T6ph to prevent LSD1 demethylation of H3K4 during AR-dependent transcription), lysosomal biogenesis in osteoclasts (via TFEB phosphorylation downstream of RANKL), vascular permeability (via occludin S490 phosphorylation), mitochondrial ROS-linked apoptosis (via p66Shc phosphorylation), autophagy suppression (via mitochondrial membrane potential regulation), and antiviral innate immunity (by phosphorylating RIG-I at S8/T170 to suppress TRIM25-mediated ubiquitination and IFN induction), while being regulated by scaffold proteins RACK1 and TRPC3 for spatial control of its activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PRKCB (PKCβ) is a diacylglycerol/Ca2+-activated serine/threonine kinase that transduces receptor-proximal signals into transcriptional, cytoskeletal, metabolic, and chromatin outputs across immune, vascular, skeletal, and neuronal contexts [#0, #2, #3]. In B-cell receptor signaling it occupies a central node: it is required to recruit and activate the IKK complex in lipid rafts to drive NF-κB-dependent survival [#0], acts upstream of CARMA1 phosphorylation and CARMA1/Bcl-10/MALT-1 assembly [#25], and simultaneously imposes negative feedback by phosphorylating a conserved serine in the Btk Tec-homology linker to limit Btk membrane recruitment [#1]. Beyond signaling, PKCβI functions as a chromatin-modifying kinase, writing the histone mark H3T6ph to block LSD1-mediated demethylation of H3K4 and thereby sustain androgen-receptor- and EWSR1-FLI1-driven transcription [#2, #10]. It controls transcription-factor activity and organelle programs downstream of RANKL by phosphorylating TFEB to drive lysosomal biogenesis for bone resorption [#3] and by inactivating GSK-3β to induce NFATc1 during osteoclastogenesis [#35]. PKCβ further phosphorylates a broad substrate set to regulate vascular barrier integrity via occludin Ser490 [#8], mitochondrial ROS and apoptosis via p66Shc [#29], antiviral innate immunity by phosphorylating RIG-I at S8/T170 to suppress TRIM25-mediated ubiquitination and IFN induction [#7], and ion-channel/transporter behavior including TRPM8 and PI3Kγ p110γ [#34, #4]. Its spatial activity is constrained by scaffolds and regulators including RACK1, TRPC3, PICK1, and the lncRNA VEAL2, which target or tune the kinase at melanosomes, plasma membrane, and mitochondria [#5, #6, #37, #38].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that PKCβ is not only an activator of BCR signaling but also a built-in brake, defining how the pathway is self-limiting.\",\n      \"evidence\": \"PKCβ knockout mice plus site-directed mutagenesis of the Btk Tec-homology linker serine with Ca2+ and membrane-fractionation readouts\",\n      \"pmids\": [\"11598012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how PKCβ access to Btk is spatially or temporally gated\", \"Did not connect this feedback to the parallel NF-κB-activating arm\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed PKCβ genetically upstream of IKK in BCR survival signaling, answering where the kinase acts in NF-κB activation.\",\n      \"evidence\": \"PKCβ knockout B cells with lipid raft fractionation, IKK activity, and IκB degradation assays\",\n      \"pmids\": [\"12118249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IKK or scaffold substrate of PKCβ not identified\", \"Mechanism of IKK raft recruitment left unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed scaffold-directed targeting confers substrate and isoform specificity, explaining how PKCβ but not PKCα acts on a given organelle target.\",\n      \"evidence\": \"Melanosome purification with reciprocal Co-IP, RACK1 siRNA, DECA disruption, and tyrosinase activity assays\",\n      \"pmids\": [\"15252133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tyrosinase phosphosites not precisely mapped\", \"Generality of RACK1-PKCβ targeting beyond melanosomes untested here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Redefined PKCβI as a chromatin-modifying enzyme, showing a kinase can write a histone mark that protects an adjacent methyl mark from erasure.\",\n      \"evidence\": \"In vitro LSD1 peptide demethylation assays, ChIP, RNAi with rescue, in vitro kinase assay, and tumor xenograft\",\n      \"pmids\": [\"20228790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PRK1-primed PKCβI is recruited to specific AR promoters not fully resolved\", \"Genome-wide scope of H3T6ph not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated TRPC3 acts as both Ca2+ channel and direct scaffold, coupling DAG/Ca2+ signals to sustained PKCβ membrane residence.\",\n      \"evidence\": \"TRPC3-deficient DT40 B cells with electrophysiology, translocation imaging, Co-IP, and ERK readouts\",\n      \"pmids\": [\"20179100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the TRPC3-PKCβ interaction unknown\", \"Whether scaffold dictates substrate choice not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified PKCα/β as constitutive negative regulators of antiviral IFN signaling through direct RIG-I phosphorylation.\",\n      \"evidence\": \"Co-IP, RIG-I S8/T170 mutagenesis, gene silencing, inhibitor treatment, IFN induction and VSV resistance assays\",\n      \"pmids\": [\"22114345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How infection relieves PKCβ-mediated suppression not defined\", \"Relative contributions of PKCα versus PKCβ not separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected RANKL signaling to organelle biogenesis by mapping PKCβ phosphorylation of TFEB to lysosome-dependent bone resorption.\",\n      \"evidence\": \"Cell-based phosphorylation mapping of TFEB C-terminal serines, osteoclast-specific KO mice, lysosomal gene readouts\",\n      \"pmids\": [\"23599343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phosphorylation stabilizes TFEB mechanistically not fully resolved\", \"Crosstalk with other TFEB kinases not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended PKCβ substrate scope to lipid kinase regulation, showing it can rewire PI3Kγ away from its canonical GPCR inputs.\",\n      \"evidence\": \"In vitro kinase assay, phospho-mimetic mutagenesis, Co-IP, HDX-MS, and PKCβ knockout cells\",\n      \"pmids\": [\"23824069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequences of p110γ Ser582 phosphorylation not established\", \"Effect on PI3Kγ output magnitude beyond p84 release unquantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revised the p66Shc phosphosite assignment, refining how PKCβ controls mitochondrial ROS and apoptosis.\",\n      \"evidence\": \"In vitro kinase assay, mutagenesis of p66Shc Ser139/Ser213, ROS and cell-death readouts, PKCβ knockout cells\",\n      \"pmids\": [\"27624939\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Contradicts prior Ser36 model and not independently confirmed\", \"Upstream activation of PKCβ in this cascade not detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a specific occludin phosphosite (S490) through which PKCβ governs vascular permeability and hemorrhagic risk.\",\n      \"evidence\": \"MCAO model in tPA-/- mice, S490A occludin knock-in, PKCβ inhibition, permeability and hemorrhage readouts\",\n      \"pmids\": [\"35576527\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How tPA activates PKCβ upstream not mechanistically mapped\", \"Whether other junctional substrates contribute not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed PKCβ2 activity is tuned by a noncoding RNA competing with its lipid activator, adding an RNA-level layer of kinase regulation.\",\n      \"evidence\": \"VEAL2 pulldown with PRKCB2 bait, kinase activity assays, zebrafish veal2 KO, HUVEC permeability and rescue experiments\",\n      \"pmids\": [\"34180064\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of VEAL2-DAG competition not resolved\", \"Generality across PKCβ-dependent tissues untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single kinase achieves substrate, isoform, and subcellular selectivity across chromatin, mitochondria, plasma membrane, and organelles remains the central unresolved question.\",\n      \"evidence\": \"No single study integrates the scaffold (RACK1, TRPC3, PICK1) and RNA (VEAL2) targeting mechanisms with the full substrate repertoire\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model linking spatial targeting to substrate choice\", \"Isoform-specific (βI vs βII) functional partitioning incompletely defined\", \"Structural basis of most substrate recognitions unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 3, 7, 8, 29, 4, 34, 36]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 3, 8, 7, 29]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [2, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 14, 33]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [18, 37]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 10]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 7, 25]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 6, 26, 37]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 10, 35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RACK1\", \"TRPC3\", \"PICK1\", \"RBCK1\", \"PKD1\", \"RIG-I\", \"Btk\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}